Pharma VC Funds

Bragiel Brothers is an early-stage venture capital firm founded in 2016 by brothers Paul and Dan Bragiel, based in San Francisco. The fund primarily invests in pre-seed, seed, and Series A rounds, focusing on high-growth industries such as SaaS, fintech, AI, machine learning, and developer tools. Known for its global outlook, the firm has invested in over 60 companies across various regions and industries. Some notable portfolio companies include unitQ, Token Transit, Inspectify, and Memfault. These investments highlight Bragiel Brothers' commitment to backing innovative startups that tackle critical challenges in sectors like big data, IoT, and software development. What sets Bragiel Brothers apart is their hands-on approach, often providing mentorship and strategic guidance to founders alongside capital. This involvement has led to successful exits, including companies like Punchh and Replay, and has positioned Bragiel Brothers as a key player in nurturing early-stage innovation. The firm's leadership, led by Paul and Dan Bragiel, brings extensive entrepreneurial experience, having advised or invested in top-tier companies like Uber, Niantic (of Pokémon Go fame), and Unity. With this deep network and focus on transformative technology, Bragiel Brothers continues to be a valuable partner for early-stage startups looking to scale globally.

Brand Foundry Ventures is a venture capital firm based in New York, focusing on early-stage investments in consumer brands. Established in 2014 by Andrew Mitchell, the firm has built a portfolio that includes notable companies like Allbirds, Eden Health, and The Wing​. The firm typically leads Series Seed and Series A financing rounds, investing in a wide range of industries such as food and beverage, health care, and consumer technology. Recent investments include Lucky F*ck, Ledgebrook, and Local Infusion​. Brand Foundry Ventures prides itself on its hands-on approach, supporting startups with strategic guidance and leveraging its extensive network to help founders scale their businesses. The firm has made over 120 investments and has had 37 successful exits, showcasing its ability to identify and nurture high-potential startups.

BrandProject is a venture capital firm based in Toronto, Ontario, founded in 2013 by Andrew Black, Andrew Bridge, Jay Bhatti, and Sarah Prevette. The firm specializes in investing in early-stage consumer product, service, and technology companies. BrandProject operates by partnering with founders to accelerate, incubate, and scale their businesses, providing both financial support and operational expertise. BrandProject has raised $54 million for its first venture fund, BrandProject Capital Fund LP, which allows the firm to support founders beyond the early stages of development. The firm typically invests between $500,000 and $5 million in companies, depending on the stage of the startup. They focus on companies that have the potential to disrupt their industries and bring new, innovative products to market. The firm has a strong track record, having invested in 22 companies since its formation. Notable exits include Freshly, which was acquired by Nestle for $1.5 billion, and Hello Products, which was acquired by Colgate-Palmolive. BrandProject's approach involves active participation in the development of their portfolio companies, providing strategic planning, operational support, marketing depth, and more to help these businesses succeed. BrandProject's investment portfolio includes companies like Daily Harvest, Clutch, and Peachy. They continue to focus on identifying market disruptors and supporting their growth to build the iconic consumer brands of tomorrow.

Bread and Butter Ventures, based in Minneapolis, Minnesota, is an early-stage venture capital firm that invests globally while leveraging the region's strong corporate connections and industry expertise. Founded in 2017, the firm focuses on several key sectors including health tech, food tech, and enterprise SaaS. Their portfolio includes notable investments such as Ducky, an automation and workflow software company; Chiyo, which focuses on food and agriculture technology; SocialCrowd, a platform for enterprise applications; and Nest Collaborative, a health tech company providing virtual lactation support. They have made a total of 87 investments, emphasizing their active involvement in the startup ecosystem. Bread and Butter Ventures has also seen successful exits, including Upsie, a technology company that was acquired, and Spoonshot, which was also successfully exited. The firm is led by Managing Partners Brett Brohl and Mary Grove, who bring extensive experience in technology and early-stage investing.

Breakout Labs, founded in 2012 as part of the Thiel Foundation, is an incubator and venture fund that supports early-stage, deep science companies with radical and emerging technologies. The fund provides up to $350,000 in initial funding and extensive support for startups that are too speculative for traditional venture capitalists. Breakout Labs focuses on companies at the intersection of technology, biology, materials, and energy, aiming to transition groundbreaking scientific discoveries from the lab to the market​. Notable portfolio companies include SciBac, which targets antibiotic-resistant diseases through microbiome science, and Azitra, which leverages the skin’s microbiome to treat skin diseases. Other innovative investments include ZymoChem, which develops sustainable chemical production processes, and EpiBone, which grows custom bones using 3D imaging and stem cells​. Breakout Labs has a history of significant follow-on funding for its portfolio companies, totaling over $1 billion. This success underscores their commitment to supporting the entire lifecycle of their investments, from seed to scale. The team, led by Managing Partners Lindy Fishburne and Julia Moore, includes experts who provide strategic guidance and leverage a vast network of founders, corporate partners, and advisors.

Breakout Ventures is a San Francisco-based venture capital firm founded in 2016, focused on early-stage investments in creative bioscience companies. The firm is dedicated to supporting startups that leverage the convergence of biology, chemistry, and technology to develop bio-based solutions aimed at improving human health and sustainability​. Breakout Ventures has raised significant capital, including a $112.5 million Fund II, to back innovative companies at the intersection of technology and biology. Their investment portfolio includes companies like Immusoft, which is working on genetically modifying B cells for sustained therapeutics, and Checkerspot, which uses synthetic biology to produce bio-derived oils​. The firm's investment strategy targets areas such as synthetic biology, cell and gene therapy, biomanufacturing, and carbon transformation, supporting companies from seed to scale. Notable portfolio companies include Cytovale, which focuses on diagnosing immune-mediated diseases, and Ecovative Design, which uses mycelium technology for sustainable materials. The Breakout Ventures team, led by managing partners Lindy Fishburne and Julia Moore, brings extensive experience in supporting science-driven companies. The firm originated from Breakout Labs at the Thiel Foundation, which has a strong history of advancing early-stage deep science startups​.

Breakthrough Energy Ventures, part of the Breakthrough Energy network founded by Bill Gates, focuses on financing and scaling companies that aim to eliminate greenhouse gas emissions globally. With over $3.5 billion in committed capital, BEV invests in more than 110 cutting-edge companies across various stages, from seed to growth. The firm targets technologies capable of significantly reducing greenhouse gases, aiming for at least half a gigaton reduction annually. Key areas of investment include clean hydrogen, long-duration energy storage, sustainable aviation fuel, direct air capture, and green manufacturing. BEV supports companies like H2Pro, which innovates in green hydrogen production, and Heirloom, focused on cost-effective carbon removal. BEV’s strategy involves more than just funding; it provides comprehensive support, including technical, operational, market, and policy expertise to help companies overcome scaling challenges. This holistic approach ensures that new climate technologies can transition from development to widespread commercial adoption. The team at BEV includes experts like Eric Toone, Technical Lead of the Investment Committee, and Megan Wenrich, Vice President of Development. These professionals bring a wealth of knowledge and experience to guide the firm’s investments and initiatives.

Breyer Capital is a premier venture capital firm founded by Jim Breyer in 2006. The firm focuses on catalyzing high-impact entrepreneurs across various sectors, including artificial intelligence, digital health, and fintech. Notable investments from Breyer Capital include Facebook, Spotify, 23andMe, and Zoox, with Zoox being acquired by Amazon. Breyer Capital invests in early-stage startups, particularly those in the AI, healthcare, and consumer tech industries. The firm's approach is founder-centric, emphasizing long-term partnerships and hands-on engagement. They typically participate in pre-seed, seed, and Series A funding rounds. Geographically, Breyer Capital has a broad focus, investing in companies across the United States, Europe, and beyond. The firm is headquartered in Menlo Park, California, but also has a significant presence in Austin, Texas. Key figures at Breyer Capital include founder Jim Breyer and partner Daniel Breyer. The team is known for its deep industry connections and strategic guidance, supporting portfolio companies with both capital and mentorship. Breyer Capital's recent investments include Atropos Health, Nimble Robotics, and Elemental Cognition, highlighting their commitment to innovative solutions in AI and healthcare. The firm's long-term vision and robust support structure make it a vital player in the venture capital landscape.

BrightEdge Fund is the philanthropic impact investment arm of the American Cancer Society (ACS), established in 2019. Headquartered in Kennesaw, Georgia, BrightEdge focuses on accelerating the commercialization of innovations in cancer care. The fund aims to reduce cancer mortality, alleviate pain and suffering, and advance health equity by investing in for-profit, early-stage companies developing cancer-focused therapeutics, diagnostics, and technologies. Notable investments in BrightEdge’s portfolio include Checkmate Pharmaceuticals, an immunotherapy drug developer; Freenome, a biotech company specializing in early cancer detection through liquid biopsy; and TailorMed, which provides patient financial navigation software. The fund has also invested in Catena Biosciences and Clasp Therapeutics. BrightEdge has a strong track record of exits, with companies like Castle Biosciences going public and Tmunity being acquired. The fund leverages the ACS’s extensive research and expertise to mitigate risks associated with health science investments. This affiliation allows BrightEdge to provide valuable insights into the competitive landscape and regulatory environment, enhancing the potential for successful commercialization of its portfolio companies​. Managed by a team of experienced professionals, including Managing Director Alice Pomponio, BrightEdge also serves as a follow-on investor and board observer, working alongside prominent venture capital firms to support its mission. The fund’s current fundraising target is $100 million, aiming to sustain ACS’s life-saving programs and further its impact.

BrightEdge is the innovation and impact investment arm of the American Cancer Society (ACS), founded in 2018 and based in Kennesaw, Georgia. A donor-funded philanthropic impact fund, BrightEdge invests in for-profit, early-stage companies developing cancer-focused therapeutics, diagnostics, medical devices, and enabling technologies. Through the end of 2024, the fund has deployed $52 million across 22 companies, with 15 active portfolio companies holding potential to impact 13.4 million patients. The fund invests globally — across the United States, Canada, Europe, and Asia-Pacific. Investments are aligned with ten American Cancer Society mission priority areas, including cancer health equity, patient survivorship, disease prevention, clinical trial accessibility, and care quality. Recent portfolio companies include Signify Bio (in vivo therapeutics, 2024). BrightEdge also runs the BrightEdge Entrepreneurs program to support founders navigating the early stages of cancer innovation. Managing Director Alice Pomponio brings experience from Red Sky Partners and teaches biomedical innovation at MIT; Director of Investments Lucas de Breed leads deal sourcing and execution. BrightEdge distinguishes itself from pure financial investors by reinvesting all financial returns back into the American Cancer Society's scientific and patient advocacy programs, making every exit outcome directly compound the mission. The fund operates with a dual mandate: achieving genuine venture returns while ensuring the ACS remains a financially self-sustaining engine for cancer research for decades ahead.

Brightlands Venture Partners is a venture capital firm based in Geleen, Netherlands, with a strong focus on investing in startups and scale-ups that address key societal challenges in sustainability and health. Established in 2014, the firm manages several funds, including Brightlands Agrifood Ventures, BVP Fund IV, Chemelot Ventures, and Limburg Ventures, with a combined capital of approximately €120 million. The firm primarily invests in sectors like renewable chemistry, regenerative medicine, agri-food, and digital technologies, aiming to support companies that contribute to a sustainable and healthier future. Brightlands Venture Partners has a diverse portfolio of over 70 companies, including Qorium, a pioneer in cell-cultured leather, and PL BioScience, a leader in sustainable cell culture media. Their investment strategy is not only about providing capital but also involves active involvement and support in scaling the companies, leveraging their deep sector expertise. The leadership team at Brightlands includes experienced professionals like Casper Bruens, Marcel Kloosterman, and Kim de Boer, who collectively bring decades of experience in venture capital and the life sciences industry. Their approach is characterized by a strong emphasis on impact investing, aligning financial returns with measurable societal impact.

Broadview Ventures, founded in 2008 and headquartered in Boston, Massachusetts, is a venture capital firm focused on investing in early-stage life sciences companies. The firm specializes in cardiovascular and neurovascular diseases, aiming to bridge the translational gap between scientific research and clinical application. Broadview Ventures has a robust portfolio that includes companies such as DecImmune Therapeutics, which develops therapies to mitigate injury post-myocardial infarction, and FineHeart, a French medical device company creating innovative cardiac support technologies. Other notable investments include GI Windows, developing non-surgical approaches for treating chronic diseases, and Adient Medical, focusing on absorbable medical devices. The firm has made 79 investments and achieved several successful exits, including Cardialen, VentriNova, and Renovacor. Broadview's investment strategy leverages their extensive industry expertise and network to support companies from seed through later stages of development. Broadview Ventures is led by a team of experienced professionals dedicated to advancing healthcare through innovative solutions. Their strategic focus and targeted investments aim to address unmet medical needs, ultimately improving patient outcomes and advancing the field of cardiovascular and neurovascular health.

Brooklyn Bridge Ventures (BBV), founded in 2012 by Charlie O'Donnell, is a pioneering early-stage venture capital fund based in Brooklyn, New York. BBV primarily focuses on leading or co-leading pre-seed and seed rounds, targeting startups in the New York City area that have raised less than $750,000 in prior funding rounds. BBV has a diverse portfolio, investing in sectors such as B2B SaaS, eCommerce, Fintech, Foodtech, and Healthcare. Some of their notable investments include Hungryroot, Brigit, and Yuvo Health. These companies have seen significant growth and success, reflecting BBV's ability to identify and nurture promising startups. The firm is known for fostering a strong community among founders and professionals, providing extensive support and guidance to early-stage startups. They typically invest around $350,000, focusing on companies with well-researched ideas, working prototypes, or early traction with users or revenue. As of May 2023, BBV announced that it would no longer be making new investments. Despite this, the firm continues to support its existing portfolio companies, helping them navigate growth and sustainability challenges. For startups seeking engagement, BBV's legacy emphasizes the importance of strong preparation and clear demonstration of potential.

Btomorrow Ventures (BTV) is the corporate venture capital arm of British American Tobacco, established in 2020 and headquartered in London. BTV focuses on building transformative and innovative businesses across sectors such as consumer brands, digital transformation, new technologies, and future sciences, with a strong emphasis on Environmental, Social, and Governance (ESG) criteria. BTV has made notable investments in startups like FlexSea, a UK-based company pioneering sustainable, seaweed-derived bioplastics, and Open Book Extracts, a cannabinoid innovation house in North Carolina. Their portfolio includes diverse companies such as Awake Chocolate in Canada, offering functional caffeinated chocolates, and Hesperos in Florida, known for their Human-on-a-Chip® technology​. The firm typically participates in early to growth-stage funding, with an average check size of $1 million. BTV is known for leading investment rounds and has a keen interest in companies that align with their sustainability and innovation goals. They actively collaborate with their portfolio companies through initiatives like Btomorrow Labs, providing strategic support and global distribution channels. Led by Managing Director Juan Palacios, the BTV team operates primarily from London, offering a blend of financial investment and strategic partnerships to accelerate the growth of ambitious founders and their disruptive technologies.

Buckley Ventures, founded in 2020 by Joshua Buckley and based in San Francisco, focuses on early-stage venture capital investments. The firm has made 35 investments across various sectors including hardware, software, and fintech. Notable investments include Rain AI, a company in the hardware industry; Framework, which specializes in consumer electronics; and Symbolica AI, a firm developing artificial intelligence solutions. Buckley Ventures has also invested in NexHealth, a healthcare software company, and Porter Finance, a trading platform. The firm has seen successful exits from companies like Whereby and ScienceIO. The team, led by Joshua Buckley and supported by Jonathan Choi and Paul Barnes, emphasizes supporting innovative startups with strong growth potential. Buckley Ventures aims to back companies that are poised to make significant impacts in their respective fields, leveraging their expertise and network to help these startups scale effectively.

Bullish, headquartered in New York City, is an early-stage venture capital firm that focuses on disruptive consumer businesses. Established in 2015, Bullish invests primarily in pre-seed to Series A rounds, with investments ranging from $500,000 to $3 million. The firm has a strong emphasis on leveraging cultural insights and innovative strategies to support its portfolio companies. Bullish's portfolio includes a range of successful and innovative companies. Notable investments include Captain Experiences, a platform for booking guided outdoor adventures; CUUP, a direct-to-consumer lingerie brand; Function of Beauty, which offers customizable hair, skin, and body care products; and FixMyCar, a mobile auto repair service. Other significant investments include Hello Cake, a wellness brand, and Dirty Labs, a company focused on eco-friendly cleaning products. The firm prides itself on providing more than just capital. They offer strategic marketing, branding, and operational support to help their portfolio companies scale effectively. The team at Bullish includes experienced marketers, strategists, and creatives who work closely with founders to navigate the challenges of growing a business.

Bullnet Capital is a venture capital firm based in Madrid, Spain, specializing in high-technology startups. Founded in 2001 by Javier Ulecia and Miguel del Cañizo, Bullnet Capital focuses on companies with proprietary, breakthrough technologies resulting from significant scientific or technical efforts. They seek startups that have sustainable competitive advantages and can stand the test of time. The firm primarily invests in sectors such as computer hardware, semiconductors, software, and healthcare devices. Their investment strategy emphasizes a hands-on approach, where they not only provide financial support but also strategic and managerial assistance to help companies navigate through their growth phases. Bullnet typically invests between €500,000 and €2,000,000 in early-stage startups. Notable portfolio companies include Digital Legends, Anafocus, and Oncovision, which have benefited from Bullnet's extensive support in both financial and strategic dimensions. The team is led by experienced professionals such as Javier Ulecia, who has a background in aeronautical engineering and an MBA from HEC Paris, and Miguel del Cañizo, a telecom engineer with advanced studies in nanotechnology and photonics. Bullnet Capital's approach focuses on fostering deep, long-term relationships with its portfolio companies, ensuring they have the necessary resources and guidance to succeed in competitive and rapidly evolving markets.

Bullpen Capital, established in 2010, is a venture capital firm based in San Francisco that specializes in post-seed investments. Their focus is on startups that have found product-market fit but are often overlooked by traditional venture capital due to various factors such as market size or early-stage revenue metrics. Bullpen Capital has funded over 100 companies, leveraging their expertise to help these businesses achieve significant milestones within a short period. Notable investments by Bullpen Capital include companies like FanDuel, Grove Collaborative, and Life360, all of which have achieved notable exits. Other significant portfolio companies include IPSY, Braze, and Carbon Health, reflecting their diverse investment strategy across consumer products, enterprise software, health tech, and more. The team at Bullpen Capital includes experienced professionals like co-founder Paul Martino and partners Eric Wiesen and Richard Melmon. Their combined experience spans across various industries and operational roles, providing portfolio companies with robust support and strategic guidance. Bullpen Capital continues to focus on sectors such as e-commerce, health, and enterprise applications, ensuring their portfolio companies receive the necessary resources and mentorship to scale effectively.

Business Finland is a public organization under the Finnish government that aims to support innovation, economic growth, and sustainable development in Finland. Established in 2018 from a merger between Tekes (the Finnish Funding Agency for Innovation) and Finpro (an export and investment promotion agency), Business Finland offers various services including innovation funding, internationalization support, and investment promotion. Its mission is to accelerate the global success of Finnish companies while positioning Finland as a competitive and attractive destination for foreign investments. Business Finland plays a significant role in promoting Finnish industries globally, particularly focusing on sectors like ICT, cleantech, bioeconomy, health, and digitalization. The organization is also deeply committed to sustainability, which is central to its strategy through 2025. It works to foster collaboration between research institutions, businesses, and international stakeholders, driving systemic change in addressing global challenges like climate change. Additionally, Invest in Finland, a key branch of Business Finland, actively attracts foreign direct investment, helping foreign companies explore opportunities in Finland. This initiative strengthens local ecosystems, creating thousands of jobs annually, particularly in high-growth sectors. With over 760 specialists spread across 40 international locations and 16 offices in Finland, Business Finland remains a cornerstone in fostering innovation and economic development within Finland's vibrant tech ecosystem.

Butterfly Ventures, established in 2012, is a leading seed-stage venture capital firm based in Helsinki, Finland, with additional offices in Oulu, Stockholm, Tallinn, and Copenhagen. The firm focuses on deep tech and hardware startups in the Nordics and Baltics. Their investment portfolio includes companies such as Wolt and Supercell, showcasing their commitment to backing transformative technology companies. Butterfly Ventures typically invests in pre-seed, seed, and early-stage rounds, with check sizes ranging from €100,000 to €2 million. They emphasize sustainable and science-based innovations, aligning with the EU's Article 8 and Sustainable Finance Disclosure Regulation (SFDR). Their latest fund, Butterfly Venture Fund IV, raised an initial €47 million, aiming for a total of €100 million to support groundbreaking startups across the region. The team at Butterfly Ventures includes experienced professionals like Juho Risku, co-founder and partner, who has a strong background in digital technologies and entrepreneurship. Other key members include Ville Heikkinen, known for his expertise in VC financing and M&A, and Tanya Horowitz, who brings a wealth of experience from her background in asset management and M&A investment banking in New York. Butterfly Ventures is deeply integrated into the Nordic startup ecosystem, actively seeking companies that have the potential for significant societal, environmental, and economic impact. Startups looking to partner with Butterfly Ventures should focus on innovative solutions that address major global challenges, particularly in deep tech and hardware sectors.

Byers Capital, managed by Blake Byers, is a San Francisco-based family office that focuses on early-stage investments in technology and biotech sectors. Founded in 2021, the firm has quickly established a diverse portfolio, including investments in high-profile companies like Neuralink, NewLimit, and Benchling. Byers Capital is known for its strategic investments in Series A and B rounds, particularly in the healthcare and enterprise applications sectors. The firm primarily invests in the United States but has also made select international investments, such as in the Netherlands. Byers Capital leverages Blake Byers' extensive experience as a former partner at Google Ventures, where he was involved in several successful exits, including companies like Robinhood and Grail. This deep expertise in both venture capital and scientific research allows Byers Capital to support its portfolio companies with not just capital, but also strategic guidance and industry connections​.

ByFounders, established in 2017, is a venture capital firm focused on early-stage investments in the Nordic and Baltic regions. The firm, based in Copenhagen and Stockholm, is known for its collective approach, leveraging a network of successful founders and operators to support its portfolio companies. ByFounders targets pre-seed and seed stage startups, particularly those in industries such as fintech, insurtech, AI, and SaaS. Notable investments include companies like SafetyWing, a global social safety net provider; Uizard, which uses machine learning to turn sketches into digital prototypes; and Normative, which provides carbon accounting software. The firm's investment strategy is deeply rooted in its community, known as the byFounders Collective, which consists of over 40 experienced Nordic and Baltic founders and operators. This collective offers portfolio companies operational expertise and a global network, helping them scale internationally. For example, companies like Corti, an AI health tech startup, and Monta, an EV charging management platform, have benefited from this extensive support network. ByFounders has made significant strides in promoting diversity within its investments. Over half of its portfolio companies have diverse founding teams, aligning with their commitment to fostering inclusive growth in the startup ecosystem.

C2 Ventures is an early-stage venture capital firm established in 2014 by Chris Cunningham and Matt Olivo. The firm focuses on investing in companies developing enterprise software and robotics solutions for legacy industries. Their goal is to provide these companies with the necessary capital and strategic support to improve productivity, capital efficiency, and profit margins. Additionally, C2 Ventures has a strong interest in clean-tech and sustainability solutions. C2 Ventures has raised several funds, including C2V Capital Partners I and II, and the Tributary Fund, which targets pre-seed investments. They provide a hands-on approach, assisting portfolio companies with revenue growth, market traction, cash management, and strategic pivots or exits. The firm emphasizes building strong relationships with founders and leveraging the expertise of their extensive network of successful entrepreneurs and tech executives. Their portfolio includes a diverse range of companies such as Paladin, Driver Technologies, OmniX Labs, and Argyle. The team at C2 Ventures brings extensive experience in asset management, startup growth, and operational expertise, ensuring their portfolio companies receive comprehensive support to achieve success.

C4 Ventures is a distinguished European venture capital firm established in 2012 by Pascal Cagni, a former Apple executive, with offices in Paris and London. The firm specializes in early to mid-stage investments in technology-driven startups, particularly those targeting expansion into European markets. C4 Ventures’ impressive portfolio includes notable investments in companies such as Graphcore, Riskified, and Foursquare. They are recognized for their strategic support and capital, which have been pivotal in helping businesses like Anki and Clippings scale successfully. The firm focuses on sectors including consumer hardware, digital media, and e-commerce, with recent investments in innovative companies like VoltR and Refurbed. C4 Ventures typically leads funding rounds and offers hands-on assistance to their portfolio companies, leveraging the extensive industry experience of their team, including co-founder Boris Bakech and partner Michel Sassano. For startups aiming to engage with C4 Ventures, it's essential to demonstrate a clear path to market leadership and scalability. The firm values innovative approaches and strong market potential, evidenced by their active investment and exit strategies, including significant exits like Riskified and Trouva.

Caffeinated Capital is an early-stage venture capital firm founded in 2013 by Raymond Tonsing and based in San Francisco, California. The firm focuses on investing in transformative technology companies from inception and supporting them throughout their growth stages. Caffeinated Capital has a diversified portfolio across sectors such as consumer, healthcare, fintech, defense, and cryptocurrency. Notable investments include companies like Affirm, Pluto, and Gigster, with exits such as Zoox (acquired by Amazon) and CTRL-Labs (acquired by Meta). The firm has a strong track record of backing successful startups that later attract significant follow-on funding from other major investors. Caffeinated Capital typically invests in pre-seed, seed, and Series A rounds, with an average check size ranging from $2 million to $12 million. The firm is highly selective, often partnering with founders who demonstrate a unique vision and the resilience to bring transformative ideas to fruition. The team at Caffeinated Capital, led by Raymond Tonsing, is known for its hands-on approach, providing strategic guidance, mentorship, and leveraging its extensive network to support portfolio companies. The firm has a global investment outlook but maintains a strong presence in major US tech hubs, particularly San Francisco.

Caixa Capital Risc, established in 2004 and based in Barcelona, Spain, is the venture capital arm of CriteriaCaixa. The firm focuses on investing in innovative companies at their initial and growth stages, particularly in Spain and Portugal. Caixa Capital Risc specializes in three main areas: Information Technology, Life Sciences, and Industrial Technologies. The firm typically invests in rounds ranging from pre-seed to Series B, with investment amounts varying from $500,000 to $5 million. Notable sectors they invest in include analytics, AI, cloud infrastructure, developer tools, edtech, fintech, healthcare services, and robotics. Their extensive portfolio includes companies like Build38, MedLumics, and Recognai, showcasing their diverse investment interests. Caixa Capital Risc is committed to supporting its portfolio companies not only financially but also through strategic guidance and leveraging its extensive network. They have a history of successful exits and are considered a key player in the Spanish and Portuguese startup ecosystems.

Cake Ventures, founded by Monique Woodard, is a venture capital firm that focuses on investing in early-stage companies poised to capitalize on significant demographic shifts. Woodard's investment strategy is built around three key areas: aging and longevity, the increasing spending power of women, and the rise of a new majority as people of color become the fastest-growing consumer groups in the U.S. With a $17 million fund, Cake Ventures primarily invests in pre-seed and seed-stage companies, typically writing checks between $200K and $750K. The firm is committed to supporting startups that address the needs of tomorrow's internet users, particularly those influenced by demographic changes. This includes companies like Mama Foods, a grocery delivery service for the U.S. Latino community, and Guaranteed, a company reimagining hospice care. Woodard's approach is unique in the venture capital landscape, as she emphasizes not just the business potential but also the social impact of these demographic trends. Her firm has backed 12 companies so far, with a significant portion led by women.

Calculus Capital, founded in 1999 by John Glencross and Susan McDonald, is a UK-based venture capital firm focusing on Enterprise Investment Schemes (EIS) and Venture Capital Trusts (VCT). The firm invests in early-stage companies in high-growth sectors such as technology, healthcare, and entertainment. The Calculus VCT offers a diversified portfolio of 30-40 UK companies, providing development and scale-up capital. Investors benefit from tax-efficient opportunities, including 30% income tax relief and tax-free capital gains and dividends if shares are held for at least five years. The Calculus EIS Fund targets Knowledge Intensive Companies, offering similar tax benefits and aiming for a return of £2 for every £1 invested. Calculus Capital is known for its strategic, hands-on approach, supporting companies with strong business models and significant growth potential. The firm's experienced team from leading financial institutions ensures robust support and guidance, contributing to successful exits like those to Microsoft and SAP.

Calm/Storm Ventures, based in Vienna, Austria, is a boutique venture capital firm and exclusive founder network that focuses on early-stage investments in digital health and wellbeing startups. The firm is known for its emphasis on purpose-driven founders who aim to improve life, health, and wellbeing. Calm/Storm Ventures has a distinctive track record of investing in projects that address sensitive and often overlooked areas such as infertility, sexual wellness, mental health, and chronic conditions. Founded in 2020, Calm/Storm Ventures targets super-early stage companies, including pre-seed, seed, and (pre-)Series A rounds. The firm has built a diverse portfolio with investments in companies like Biloba, an instant messaging app for pediatric consultations; Healee, a digital health platform for telehealth services; and Thymia, which aims to make mental health objectively measurable. The investment team at Calm/Storm is composed of founders and entrepreneurs who bring extensive experience and a hands-on approach to supporting portfolio companies. The team includes Lucanus Polagnoli as Founding Partner and CEO, Philippa Allen as Junior Investment Manager, and Johannes Blaschke as Principal. The firm also boasts a high level of diversity, with 50% of its portfolio companies having diverse teams, and 60% of its board members being female. Calm/Storm Ventures is not only a capital provider but also offers deep expertise in business development, market positioning, and global connectivity, helping startups navigate the complexities of the healthcare and wellbeing sectors.

Cambridge Angels, established in 2001, is a prominent UK business angel network based in Cambridge. The group comprises over 60 affluent investors who provide smart capital and mentorship to startups and scale-ups primarily in the UK, focusing on science, engineering, and healthcare technology sectors. They have invested over £150 million in more than 120 companies. Notable investments by Cambridge Angels include companies like Paragraf, Arecor, Eagle Genomics, Privitar, and Healx. The group supports these companies not just financially, with typical investments ranging from £150,000 to £1.5 million, but also through strategic guidance, leveraging their extensive experience as successful entrepreneurs. Cambridge Angels is known for their commitment to fostering innovation without charging founders to pitch, ensuring that the entrepreneurial focus remains on development and growth. This investor group also holds educational sessions for portfolio companies, covering critical topics such as exit strategies and leadership development.

Cambridge Innovation Capital (CIC) is a venture capital firm based in Cambridge, UK, specializing in investing in deeptech and life sciences startups. Established to leverage the rich innovation ecosystem around the University of Cambridge, CIC manages over £500 million across its funds, focusing on supporting early to growth-stage companies. The firm plays a strategic role in fostering innovation by backing ventures that emerge from the Cambridge cluster, including university spinouts and collaborations with research institutes like the Wellcome Sanger Institute. CIC's investment portfolio reflects its emphasis on groundbreaking technology, with companies like CMR Surgical, known for its Versius robotic surgery system, and PragmatIC Semiconductor, which focuses on flexible electronics. The firm also invests in biotech firms like Microbiotica, which leverages the microbiome for therapeutic purposes, and quantum computing ventures such as Riverlane. With its commitment to sustainability and a robust focus on ESG (Environmental, Social, and Governance), CIC aims to create long-term value while fostering responsible business practices. The firm not only provides capital but also strategic support, often co-investing alongside other prominent funds and facilitating connections through initiatives like DeepTech Labs and Start Codon, two accelerators designed to help startups navigate early commercial challenges. Led by Managing Partner Andrew Williamson, CIC remains deeply integrated within the Cambridge ecosystem, collaborating with universities, research hubs, and industry leaders to drive the next wave of technological breakthroughs​.

Camford Capital is a Palo Alto-based venture capital firm that focuses on investing in transformative technologies across sectors like enterprise software, consumer products, fintech, and healthcare. Founded in 2021, the firm partners with early-stage and growth-stage companies in the U.S. and Asia, seeking to back innovative solutions that have the potential to reshape industries globally. Camford has built a strong portfolio that includes notable investments such as CG Oncology and Totus Medicines, which highlight its emphasis on life sciences. Additionally, the firm has backed Viz.ai an AI-driven healthcare company, and Stori, a fintech unicorn offering credit card solutions in Latin America. The firm is particularly known for its ability to identify and support companies that leverage exponential technologies to tackle complex problems in healthcare and financial services. The leadership team at Camford consists of experienced entrepreneurs and investors, including Andrew Gu and Ali Farahanchi, who bring deep operational and investment expertise. Their strategy combines hands-on partnership with founders and an ability to co-invest with global players like General Catalyst and Khosla Ventures. Camford Capital tends to invest anywhere between $500,000 and $10 million, with a preference for leading funding rounds. Entrepreneurs seeking investment can reach out to the firm through its website for inquiries.

Canaan is a leading early-stage venture capital firm that focuses on transformative ideas in the technology and healthcare sectors. With a strong history spanning over 35 years, Canaan has invested in notable companies such as Instacart, LendingClub, The RealReal, and Match.com. The firm has managed to achieve impressive exits, including IPOs for companies like TheRealReal, Arvinas, and Day One Biopharmaceuticals. Canaan’s investment strategy covers a wide range of industries including enterprise software, consumer tech, fintech, and frontier tech. They are particularly noted for their deep involvement in healthcare, with significant investments in areas such as oncology, immunology, and neurology. Their portfolio includes companies like Dexcom, Synthekine, and Vivace Therapeutics, among others. The firm manages over $6.8 billion in assets and recently closed its thirteenth fund with $850 million to continue supporting innovative startups through their early and growth stages. This new capital will help expand their investments in robotics, AI/ML, cybersecurity, and genetically defined precision medicines​.

Canapi Ventures is a venture capital firm focused on early to growth-stage fintech companies. With the recent launch of its $750 million Fund II, Canapi has increased its total assets under management to over $1.4 billion. The firm is backed by nearly 70 financial institutions and strategic investors, known as the Canapi Alliance, which provides a unique network to support portfolio companies. Canapi's investment strategy is centered on financial technology and related sectors, including fraud and identity, financial infrastructure, lending and credit, payments, and real estate technology. They have expanded their scope to include areas like AI, cybersecurity, and climate tech with investments in companies such as DynamoFL, Island, and Crux Climate. Notable investments from Canapi's Fund I include Alloy, Built, Thoropass, and Greenlight, with successful partnerships generating significant annualized revenue and job creation. The firm typically invests between $10 million and $50 million in emerging companies and has a strong track record of leading multiple funding rounds for its portfolio companies​. Canapi Ventures is headquartered in Wilmington, NC, with additional offices in Washington, D.C., New York, and San Francisco. The team is led by experienced financial services professionals, including Managing Partners Gene Ludwig and Chip Mahan, who leverage their extensive industry connections and regulatory expertise to help portfolio companies navigate complex challenges and maximize their impact.

Cantos Ventures, established in 2016 and headquartered in San Francisco, focuses on pre-seed and seed-stage investments in frontier technologies. The firm invests in sectors such as climate tech, computational biology, aerospace, and advanced computing. Notable companies in their portfolio include Solugen, Astranis, and Public, reflecting their commitment to transformative technologies. Cantos Ventures emphasizes investing in high-potential startups tackling significant global challenges. Recent investments include Furno Materials, which raised $6.5 million for decarbonizing cement production, and Shinkei Systems, which secured $6.27 million to innovate in sustainable fish processing. The firm collaborates with co-investors like Y Combinator and 8VC, ensuring a robust support network for their portfolio companies. The team at Cantos Ventures, led by Ian Rountree and Natalie Estrella, leverages extensive experience to support founders. They adopt a hands-on approach, providing strategic guidance and access to global networks. Startups seeking investment should demonstrate strong technical capabilities and a clear vision for addressing large-scale problems. Cantos Ventures is recognized for its selective and impactful investment strategy, often leading rounds with substantial financial commitments to drive growth and innovation

Canvas Ventures is a Portola Valley-based venture capital firm founded in 2013 by Rebecca Lynn, Gary Little, and Paul Hsiao. Specializing in Series A and B investments, Canvas Ventures primarily focuses on fintech, digital health, AI, marketplaces, and logistics sectors. With a strategic emphasis on companies poised for significant growth, the firm offers more than just capital, providing extensive go-to-market expertise, sales strategy, and growth guidance to their portfolio companies. Notable investments include Luminar Technologies, which went public via SPAC in 2020, and successful ventures like Zola, Vida Health, and Transfix. Their recent fund, CV3, raised $350 million, bringing their total capital raised to $835 million. Canvas typically leads funding rounds with investments ranging from $5 million to $15 million. The firm is led by experienced partners, including Rebecca Lynn, a renowned investor with deep expertise in consumer credit and healthtech. Canvas Ventures has a mission-driven approach, deeply engaging with their portfolio companies to ensure their success. The team has also established the Canvas GTM Council, comprising top marketing and sales professionals who provide invaluable insights to portfolio companies. Canvas Ventures prefers to work with founders who are tackling transformative problems and are prepared for the long-term journey of building significant companies. They maintain a collaborative and supportive relationship with entrepreneurs, helping them navigate challenges and scale their businesses effectively.

Capagro is a Paris-based venture capital firm established in 2014, focusing on investments in the AgTech and FoodTech sectors. The firm aims to accelerate innovation and development across the agricultural and food value chains, supporting companies that offer sustainable and impactful solutions. Capagro's portfolio includes notable companies such as Naïo Technologies, which develops agricultural robotics, Cuure, a personalized health and wellness provider, and NICK'S, a snack food manufacturer. Other significant investments are in La Belle Vie, an e-commerce grocery platform, and ecoRobotix, which specializes in precision farming robotics. The firm typically invests between €1 million and €5 million per round, emphasizing early-growth companies that already have significant revenues or are close to commercialization. Capagro has made 36 investments to date, with a strategy focusing on three main segments: upstream agricultural production, downstream consumer food products, and energy efficiency innovations in the agro-industrial sector. Capagro is led by Jean-Baptiste Cuisinier and Jérôme Samson, who bring extensive experience in food, agribusiness, and venture capital. Their deep industry knowledge and strategic support have made Capagro a valuable partner for innovative startups aiming to scale and make a global impact. The firm manages assets of approximately €124 million, backed by notable investors including Bpifrance and Groupe Avril. Capagro continues to seek new investment opportunities to bridge the funding gap in the European AgTech and FoodTech industries.

Capital Factory is a prominent venture capital firm and accelerator based in Austin, Texas, that serves as a major hub for entrepreneurs across Texas. Founded in 2009, it supports early-stage tech startups through investments, mentorship, and community access. Its program emphasizes long-term engagement, providing startups with free coworking space, extensive mentorship from industry leaders, and introductions to investors. Capital Factory stands out with its robust network, which includes hundreds of mentors and partnerships with major tech companies like Amazon and Google, offering hosting credits and other resources to its portfolio companies. Capital Factory’s accelerator is not your typical boot camp. Instead, startups can immerse themselves in the program, gaining the support needed to scale, with Capital Factory taking a 1% equity stake. The firm is particularly active in sectors like artificial intelligence, digital health, education technology, and SaaS, making investments in companies such as Zen Business and Aceable. Beyond its Austin headquarters, Capital Factory has expanded its influence with programs in Dallas, Houston, and San Antonio, making it a central player in the Texas startup ecosystem.

Capricorn Partners, headquartered in Leuven, Belgium, is a leading independent manager of venture capital, growth capital, and quoted equity funds. The firm focuses on innovative companies that leverage technology as a competitive advantage, particularly in sectors such as digital technologies, health, and cleantech. Capricorn Partners manages several funds, including the Capricorn Cleantech Fund, Capricorn Digital Growth Fund, Capricorn Health-Tech Fund, and Capricorn Fusion Fund, which targets opportunities with a specific China strategy. They also manage Quest for Growth, integrating both quoted and private investments, focusing on European companies expected to produce higher than average growth in digital, health, and clean technologies. The firm has a strong commitment to ESG principles and aims to create both financial return and strategic value for its clients. Their investment philosophy is rooted in supporting innovative sectors that drive positive change, making them a pivotal player in the venture capital landscape. Capricorn’s team comprises experienced investment managers with deep technology expertise and broad industrial experience. They offer a unique mix of technology and investment expertise, creating an ecosystem that supports superior returns through the combination of investable capital, innovative ideas, capable entrepreneurship, and business management. For entrepreneurs, Capricorn Partners provides not only capital but also strategic guidance and support, leveraging their extensive network and industry knowledge to foster growth and innovation in their portfolio companies​.

Carbon Silicon Ventures, founded in 2022 and based in New York City, is a venture capital firm that invests in early-stage companies at the cutting edge of biotechnology and healthcare. With a focus on pre-seed, seed, and Series A rounds, the firm aims to back startups applying engineering and scalable technologies to revolutionize life sciences. The firm's primary sectors include lab automation, drug development, and biotech SaaS, targeting companies that use innovative methods to disrupt the healthcare landscape. Led by Nish Bhat, co-founder of Color, Carbon Silicon Ventures is deeply embedded in the biotech community, leveraging Bhat's experience in healthcare and technology to identify promising startups. The firm has already made significant investments in companies like Ansa Biotechnologies, known for its breakthroughs in synthetic biology, and Octant Bio, a leader in drug discovery​. Carbon Silicon Ventures typically writes checks ranging from $100K to $500K and focuses on U.S.-based companies. It positions itself as a high-conviction investor, supporting founders that aim to scale transformative solutions. The firm has a growing portfolio that includes promising biotech startups, aligning itself with major co-investors like Sequoia and Andreessen Horowitz. With a clear mission to apply engineering principles to healthcare, Carbon Silicon Ventures is well-positioned to make a lasting impact on the future of medicine.

Carbon13 is a venture builder focused on addressing the climate emergency by helping founders create scalable startups that contribute significantly to reducing carbon emissions. Based in Cambridge and Berlin, Carbon13’s programs support entrepreneurs from the earliest stages of ideation through to pre-seed investment. Their goal is for each venture to eventually reduce 10 million tonnes of CO2e annually once scaled. The organization has launched over 70 climatetech ventures since 2021, including notable startups like Kita, which offers the world’s first carbon removal insurance, and Materials Nexus, which uses AI and quantum mechanics to design low-carbon materials​. Carbon13's venture builder program focuses on both technical and commercial founders, fostering collaborations between scientists, engineers, and entrepreneurs to build impactful solutions. Participants gain access to a vast network of domain experts and investors, including partnerships with organizations like Barclays and EY. The program emphasizes a dual focus on achieving commercial success and measurable carbon reduction. The fund actively invests through its SEIS Funds, targeting ventures that align with its mission of achieving net-zero emissions by 2050.

Carduso Capital is a Groningen-based venture capital firm focused on supporting innovative technology companies, particularly those linked to the University of Groningen and the University Medical Center Groningen. The fund targets sectors such as life sciences, energy, and sustainability, with a special interest in spin-offs and startups leveraging university research. Carduso Capital’s investments range from €100,000 to €5 million, covering companies at various stages of growth, from seed to expansion phases. In addition to financial backing, Carduso takes an active role in providing strategic and managerial support to its portfolio companies, ensuring they have the resources and guidance needed to thrive. Their investment strategy emphasizes long-term collaboration and supports multiple financing rounds if necessary. The fund looks for businesses with completed proof-of-concept and functional prototypes that are nearing market readiness. Portfolio companies must address unmet needs with clear, realistic market-entry strategies. Some notable investments include Ivy Medical, Qdi Systems, and ViroTact, reflecting their focus on high-potential technologies within their core sectors. Led by fund managers Koos Koops, Robert Polano, and Frits Kok, Carduso Capital combines deep industry knowledge with a strong network, enabling startups to benefit from both financial and operational expertise. The team prioritizes fostering long-term success, even during challenging periods, and is deeply involved in ensuring the sustainable growth of its companies. Their active engagement and sector-specific focus make them a valuable partner for tech-driven startups seeking strategic and financial support.

Casdin Capital, established in 2012 by Eli Casdin, is a New York-based venture capital firm with a focus on life sciences and healthcare. The firm specializes in investing in companies that are at the forefront of scientific and technological advancements in areas such as molecular medicine, biotechnology, genomics, and synthetic biology. Notable investments by Casdin Capital include high-impact companies like 23andMe, Adaptive Biotechnologies, Recursion Pharmaceuticals, and Ginkgo Bioworks. These investments highlight the firm’s commitment to transformative technologies in health care, gene editing, and diagnostic platforms. Casdin Capital's strategy revolves around funding companies that leverage data and precision-based therapies to revolutionize the healthcare industry. They focus on early-stage to late-stage investments, providing substantial financial support to help these companies scale and achieve significant milestones. The firm has managed to build a robust portfolio with 250 investments and 87 exits, demonstrating a strong track record of successful investments and strategic exits. Key team members include Eli Casdin as the Founder and Chief Investment Officer, Alexandria Fisk as Chief Operating Officer, and Lawrence Canzoneri as Chief Financial Officer. The team’s expertise and deep industry knowledge enable them to identify and support innovative startups effectively. Casdin Capital's approach combines strategic investments with deep sector expertise, positioning them as a leading player in the life sciences investment landscape, actively supporting companies that are poised to make groundbreaking advancements in health and biotechnology.

AVG Funds, also known as Alumni Ventures Group, is a prominent venture capital firm that leverages the power of alumni networks to invest in innovative startups across various sectors. Founded with the mission to democratize venture capital, AVG Funds has become one of the most active venture firms globally. They manage over $200 million in assets and have made more than 115 investments in the past year alone. AVG Funds focuses on diverse industries, including AI and machine learning, health tech, fintech, cleantech, and cybersecurity. Notable investments include companies like Adventr, a media and information services platform, and Eclypsium, which specializes in cybersecurity for enterprise hardware. Their portfolio also features startups like PartySlate, a digital platform for event planning, and Venus Aerospace, a company developing high-speed transport technologies. The firm operates through a network of alumni funds associated with top universities such as Harvard, MIT, Stanford, and Yale. This structure enables AVG to tap into a vast network of alumni entrepreneurs and investors, providing a rich source of deal flow and support for portfolio companies. AVG Funds typically invests in early to growth-stage companies, with check sizes ranging from $100,000 to $2 million. They emphasize a hands-on approach, providing not only capital but also strategic guidance and connections to help startups scale and succeed.

Catalio Capital Management is a multi-strategy investment firm focused on breakthrough biomedical technology and innovative healthcare companies. Founded in 2020 by George Petrocheilos and Dr. Jacob Vogelstein, Catalio specializes in private equity, private credit, and public equities strategies, supporting companies from inception through to IPO or acquisition. The firm’s portfolio includes notable companies such as Affini-T, which is developing precision T-cell therapeutics for solid tumors, and Boost Neuroscience, focusing on therapies to combat cognitive aging and neurodegeneration. Catalio has also invested in companies like Octant, Inc., and Pheast Therapeutics, demonstrating a strong commitment to advancing precision medicines and novel cancer therapies. Catalio's strategy involves close collaboration with their portfolio companies, leveraging a network of over 36 world-renowned scientists to identify and invest in cutting-edge biomedical technologies. This approach has led to successful investments in companies like Thrive Earlier Detection, which was acquired by EXACT Sciences for $2.15 billion, and Personal Genome Diagnostics, acquired by LabCorp for $500 million.

Catalyst Health Ventures (CHV) is a Boston-based venture capital firm founded in 2000, exclusively focused on innovative early-stage MedTech companies. With over two decades dedicated to the healthcare sector, the firm invests in visionary teams developing breakthrough medical technologies that address significant global unmet clinical needs. The team comprises 13 members including three partners and one venture partner, operating from its office at 129 South Street in Boston. CHV leads rounds at the Seed and Series A stages, writing checks of $1 million to $5 million with continued participation in follow-on rounds through exit. Across 80 investments, the firm has recorded 12 portfolio exits — including acquisitions by Boston Scientific, Veracyte, Agilent Technologies, Life Technologies, and W.L. Gore & Associates, as well as Sera Prognostics' NASDAQ IPO. Key focus areas include oncology, cardiovascular disease, obesity, and women's health, spanning therapeutic devices, diagnostics, drug delivery, and digital health. Recent investments include Conformal Medical, Esperto Medical, Venova Medical, and Aria CV. CHV brings strategic insight, deep industry expertise, and a hands-on collaborative approach to every portfolio relationship. The firm's particular strength lies in helping founders navigate the distinctive regulatory and commercialization complexities of the medical device and diagnostics landscape — a path that requires far more than capital. That specialization, sustained consistently over 25 years, has made Catalyst Health Ventures one of the most experienced dedicated MedTech investors in the United States.

Catapult Ventures is one of the most experienced venture capital fund managers in the United Kingdom, founded in 1999 and headquartered in Leicester in the Midlands. The firm has successfully managed numerous discrete venture capital funds totaling approximately £130 million on behalf of public and private sector investors, completing 151 investments across its history. Key funds include the £30 million East Midlands Regional VC Fund, the £20 million West Midlands seed fund, the £30 million Catapult Growth Fund (an Enterprise Capital Fund), and the £31 million GM&C Life Sciences Fund for Greater Manchester and Cheshire. Catapult leads rounds at the Seed through Series B stages, deploying checks of £50,000 to £2 million across healthcare, life sciences, pharmaceuticals, software, and advanced manufacturing. The firm's exit track record demonstrates consistently strong multiples: R2C Online at 12.6x, Accutronics at 9.1x, Yospace at 6.9x, Oxford Cryosystems at 5.2x, Lumora at 4.7x, and Monica Healthcare at 3.6x. Other notable exits include Abzena, Left Hand Robotics, and Ergomed. The most recent investment was Array Labs at Series A in January 2026. Catapult Ventures combined operations with Opus Ventures in 2013, deepening its regional footprint and talent base. The firm's multi-decade presence in the UK Midlands — a region often underserved by London-centric capital — reflects a deliberate focus on building enduring companies from inception through exit across the full life sciences and technology innovation cycle.

Cathay Capital is a global investment firm known for its cross-border investment strategies, supporting companies across various stages from venture to growth. Founded in 2007, the firm has established a strong global presence with offices in major cities such as Paris, New York, Shanghai, and San Francisco. With over $4.5 billion in assets under management, Cathay Capital invests across sectors including healthcare, consumer goods, digital technology, and energy, aiming to foster sustainable transformation and globalization. The firm operates through several specialized funds, such as Cathay Innovation, Cathay Health, and regional initiatives like the Seaya Cathay Latam Fund. Cathay Innovation focuses on digital transformation, investing in companies at the forefront of the tech revolution, with a portfolio that includes firms like Chime, KaiOS, and Ledger. Meanwhile, Cathay Health, a €500 million fund, targets companies at the convergence of healthcare, life sciences, and technology, helping ventures scale globally with investments in firms like Tissium and Kojin Therapeutics. Cathay Capital's strategy emphasizes connecting startups with established corporations to drive innovation and expansion, leveraging its extensive network across Europe, North America, and Asia. The firm has also launched partnerships to enhance its reach, such as the collaboration with Seaya Ventures to support Latin American startups, reflecting its commitment to fostering diverse and sustainable growth globally.

Cathay Innovation, founded in 2015, is a global venture capital firm affiliated with Cathay Capital. The firm focuses on multi-stage investments in innovative startups across various sectors, including AI, fintech, digital health, consumer tech, and energy. With a presence in North America, Europe, Asia, and Latin America, Cathay Innovation leverages its global network to support entrepreneurs in scaling their businesses. Notable investments in Cathay Innovation's portfolio include Ledger, a leading provider of blockchain-based hardware wallets for cryptocurrency, and Glovo, a Spanish on-demand delivery service that was acquired by Delivery Hero. Other significant investments are Owkin, which uses AI for drug discovery and precision medicine, and Kredivo, a fintech company providing consumer loans in Indonesia. The firm has also seen several successful exits, such as the IPO of Wallbox, a smart charging company listed on the New York Stock Exchange, and the acquisition of Getaround, a peer-to-peer car sharing service. Cathay Innovation has a strong track record of identifying and nurturing high-growth companies, with multiple portfolio companies achieving unicorn status. Led by a diverse team of 45 members, including 17 partners, Cathay Innovation emphasizes a collaborative approach, providing strategic support and leveraging its extensive ecosystem to help startups thrive globally. The firm continues to drive innovation and positive impact through its investments in technology-driven companies.

Cathexis Ventures is a venture capital firm based in Houston, Texas, and serves as the venture arm of Cathexis Holdings. Established in 2018, Cathexis Ventures has a diverse investment portfolio with over 100 companies. They primarily focus on seed-stage investments but also participate in pre-seed and Series A rounds. Their investment strategy includes an 80% focus on seed, 10% on pre-seed, and 10% on Series A investments, with initial check sizes ranging from $250,000 to $1,000,000, and up to eight-figure follow-on investments. The firm invests across various sectors, including SaaS (60%), hardware (30%), and consumer (10%) products, with a geographic focus of 70% in North America and 30% internationally. Notable investments include companies like Betterhalf, an AI-enabled matchmaking platform, and BlueCargo, which focuses on smarter container movement. Other significant investments span industries such as healthcare compliance (Verifiable), construction operations (Tenderd), and carbon capture technology (Heimdal). Cathexis Ventures is led by a team of experienced investors and professionals who aim to support extraordinary founders building innovative products with speed and efficiency.